Abstract

MIRANDA, Natalia. PCSK9 inhibitors: a new era in the control of cardiovascular risk. Rev.Urug.Cardiol. [online]. 2019, vol.34, n.3, pp.356-380.  Epub Dec 01, 2019. ISSN 0797-0048.  https://doi.org/10.29277/cardio.34.3.26.

Statins are still the fundamental piece for cardiovascular risk management. Used in doses of high intensity achieve reductions in cholesterol associated with low density lipoproteins of 50%-60%.

However, in patients with severe hypercholesterolemia, statins alone or associated with ezetimibe may not be sufficient to achieve cholesterol associated with low density lipoproteins decrease targets. Such is the case of genetic dyslipidemias as familial hypercholesterolemia. Also in patients with total or partial statin intolerance, a modern pharmacological alternative is required to reduce high cardiovascular risk. In this scenario, proprotein convertase subtilisin kexin type 9 inhibitors have become a cornerstone to achieve not only a reduction never seen before of cholesterol associated with low density lipoproteins levels, but also of cardiovascular risk. These drugs are in a privilege position due to the new evidence, being effective and well tolerated, with cost as its main limitation despite its marked decline in recent years.

Keywords : PCSK9 inhibitors; Hyperlipoproteinemia Type II; Statin Intolerance; Cardiovascular risk.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )